Marty Makary, nominated by Trump to lead the FDA, faced a challenging confirmation hearing where he was pressed on various contentious issues including abortion pills, vaccine policies, and FDA staffing. Senators expressed concerns regarding his previous statements and the potential rollback of access to mifepristone, a widely used abortion medication. While Makary pledged an independent review of FDA staff cuts and claimed that his agenda includes ensuring safe school lunches, he sidestepped direct answers on the future of abortion pill access and the role of vaccine advisory committees. Despite these challenges, he appears to be on track for confirmation, as recent updates suggest a favorable outlook following a breezy Senate appearance.